ARTICLE | Cover Story

A B cell burden in prostate cancer

March 25, 2010 7:00 AM UTC

Although castration therapies such as androgen ablation are standard prostate cancer treatments, many patients develop resistance in 12-18 months.1 Now, researchers from the University of California, San Diego

and Scripps Florida have found that castration therapies themselves trigger an inflammatory response that could be partly responsible for such resistance. The findings make the case for complementing castration therapies with marketed biologics that can deplete B cells or block lymphotoxin signaling...